Related Experiment Video

Updated: May 20, 2026

Colony Formation Assay Detecting the Proliferative Capacity of LncRNA-knockdown Osteosarcoma Cells
06:13

Colony Formation Assay Detecting the Proliferative Capacity of LncRNA-knockdown Osteosarcoma Cells

Published on: January 16, 2026

Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell

Zhenfeng Duan1, Jianming Zhang, Edwin Choy

  • 1Center for Sarcoma and Connective Tissue Oncology and Department of Pathology, Massachusetts General Hospital, Boston, MA 02114, USA. zduan@partners.org

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|July 14, 2012
PubMed
Abstract

Insights

Cyclin-dependent kinase 11 (CDK11) is crucial for osteosarcoma cell survival and growth. Inhibiting CDK11 shows promise as a targeted therapy to improve patient outcomes in osteosarcoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Osteosarcoma is a primary bone cancer with limited targeted therapy options.
  • Identifying novel therapeutic targets is crucial for improving patient survival rates.

Purpose of the Study:

  • To identify kinase-based therapeutic targets for osteosarcoma.
  • To investigate the role of Cyclin-dependent kinase 11 (CDK11) in osteosarcoma progression.

Main Methods:

  • Utilized a lentiviral-based shRNA kinase library for screening.
  • Employed cell proliferation assays and siRNA to assess kinase function.
  • Validated CDK11 expression via Western blot and immunohistochemistry.
  • Evaluated CDK11's prognostic value and therapeutic potential in xenograft models.

Main Results:

  • Osteosarcoma cells exhibit high CDK11 expression.
  • Knockdown of CDK11 inhibited cell growth and induced apoptosis.
  • High CDK11 expression correlated with significantly shorter patient survival.
  • In vivo administration of CDK11 siRNA reduced tumor growth in xenografts.

Conclusions:

  • CDK11 signaling is essential for osteosarcoma cell growth and survival.
  • CDK11 represents a potential therapeutic target for osteosarcoma treatment.
  • Further research into CDK11 inhibitors may offer therapeutic benefits.

More Related Videos

MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells09:12

MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells

Published on: December 21, 2011

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...